Evidence map›Paper›PMID 18347114›Full record

ArticleAntimicrobial agents and chemotherapy2008

Biological activities of novel gyrase inhibitors of the aminocoumarin class.

Christine Anderle, Martin Stieger, Matthew Burrell, Stefan Reinelt, Anthony Maxwell, Malcolm Page, Lutz Heide

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Antibiotics (Basel, Switzerland) · 2021
    Review
  4. Article
  5. Review on plant antimicrobials: a mechanistic viewpoint.Antimicrobial resistance and infection control · 2019
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. DNA Topoisomerases.EcoSal Plus · 2015
    Review
  11. Article
  12. Article
  13. Article
  14. Challenges of antibacterial discovery.Clinical microbiology reviews · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christine AnderlePharmazeutische Biologie, Pharmazeutisches Institut, Universität Tübingen, Auf der Morgenstelle 8, Tübingen D-72076, Germany.
Martin Stieger
Matthew Burrell
Stefan Reinelt
Anthony Maxwell
Malcolm Page
Lutz Heide

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thirty-one aminocoumarin antibiotics derived from mutasynthesis experiments were investigated for their biological activities. Their inhibitory activities toward Escherichia coli DNA gyrase were determined in two different in vitro assays: an ATPase assay and a DNA supercoiling assay. The assays gave a similar rank order of the activities of the compounds tested, although the absolute 50% inhibitory concentrations (IC(50)s) obtained in each assay were different. To confirm that the compounds also acted as gyrase inhibitors in vivo, reporter gene assays were carried out with E. coli by using gyrA and sulA promoter fusions with the luxCDABE operon. A strong induction of both promoters was observed for those compounds that showed gyrase inhibitory activity in the biochemical assays. Compounds carrying analogs of the prenylated benzoyl moiety (ring A) of clorobiocin that were structurally very different showed high levels of activity both in the biochemical assay and in the reporter gene assay, indicating that the structure of this moiety can be varied considerably without a loss of affinity for bacterial gyrase. The experimentally determined IC(50)s were compared to the binding energies calculated in silico, which indicated that a shift of the pyrrole carboxylic acid moiety from the O-3'' to the O-2'' position of the deoxysugar moiety has a significant impact on the binding mode of the compounds. The aminocoumarin compounds were also investigated for their MICs against different bacterial pathogens. Several compounds showed high levels of activity against staphylococci, including a methicillin-resistant Staphylococcus aureus strain. However, they showed only poor activities against gram-negative strains.

Indexed as

Topoisomerase II InhibitorsAdenosine TriphosphatasesAminocoumarinsAnti-Bacterial AgentsDNA, SuperhelicalEnzyme InhibitorsGram-Negative BacteriaGram-Positive CocciHumansInhibitory Concentration 50Microbial Sensitivity TestsMutationNovobiocinAdenosine TriphosphatasesAminocoumarinsAnti-Bacterial AgentsclorobiocinDNA, SuperhelicalEnzyme InhibitorsNovobiocinTopoisomerase II Inhibitors

Identifiers

PMID18347114
PMCPMC2415755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.